Refractory Histiocytic and Dendritic Cell Neoplasm: Clinical Trials

2 trials for Refractory Histiocytic and Dendritic Cell Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 2

Follow Refractory Histiocytic and Dendritic Cell Neoplasm: new trials by email Literature Review of Refractory Histiocytic and Dendritic Cell Neoplasm trials Research Report on Refractory Histiocytic and Dendritic Cell Neoplasm

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)12021-05-032026-10-09
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-11-142026-09-21

Narrower conditions

Ependymoma (2)  ·  Glioma (2)  ·  Hepatoblastoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Medulloblastoma (2)  ·  Neuroblastoma (2)  ·  Neuroectodermal Tumors, Primitive, Peripheral (2)  ·  Osteosarcoma (2)  ·  Rhabdoid Tumor (2)  ·  Rhabdomyosarcoma (2)  ·  Sarcoma (2)  ·  Sarcoma, Ewing (2)  ·  Wilms Tumor (2)  ·  Lymphoma (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genetic Diseases, Inborn (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Histiocytosis (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Kidney Diseases (2)  ·  Kidney Neoplasms (2)  ·  Lung Diseases (2)  ·  Lung Diseases, Interstitial (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Male Urogenital Diseases (2)

Interventions

Magnetic Resonance Spectroscopy (1)  ·  Nuclear Medicine Department, Hospital (1)  ·  Phantoms, Imaging (1)  ·  Pharmacogenomic Variants (1)  ·  X-Rays (1)  ·  selpercatinib (1)  ·  ulixertinib (1)

Sponsors

National Cancer Institute (NCI) (2)

Countries

Puerto Rico (2)  ·  United States (2)  ·  Australia (1)

Top investigators

Andrea T Franson (1)  ·  Kieuhoa T Vo (1)

Results publications

PMID 31401903, PMID 38935895, PMID 42867148

NIH funding

U10CA180886 (2)